EasySep™人CD4+CD127low CD25+调节性T细胞分选试剂盒

采用可解离磁珠技术进行人CD4+CD127lowCD25+调节性T细胞(Tregs)的免疫磁珠分选

产品号 #(选择产品)

产品号 #18063_C

采用可解离磁珠技术进行人CD4+CD127lowCD25+调节性T细胞(Tregs)的免疫磁珠分选

产品优势

  • 在短至1小时内分离出高纯度的人CD4+CD127lowCD25+ Tregs
  • 无需清洗去除EasySep™ Releasable RapidSpheres™可解离磁珠
  • 可从同一样本中分离CD4+CD25-应答T细胞(可选)

产品组分包括

  • EasySep™人CD4+CD127low CD25+调节性T细胞分选试剂盒(产品号 #18063)
    • EasySep™人CD25正选抗体混合物,1 mL
    • EasySep™人CD127high去除抗体混合物,1 mL
    • EasySep™人CD4+ T细胞富集抗体混合物,1 mL
    • EasySep™ Releasable RapidSpheres™磁珠,1 mL
    • EasySep™ Dextran RapidSpheres™磁珠,2 x 1 mL
    • EasySep™ Release 缓冲液,2 x 1 mL
  • EasySep™人CD4+CD127low CD25+调节性T细胞分选试剂盒(产品号 #100-1136)
    • EasySep™人CD25正选抗体混合物,1 x 10 mL
    • EasySep™人CD127high去除抗体混合物,1 x 10 mL
    • EasySep™人CD4+ T细胞富集抗体混合物,1 x 10 mL
    • EasySep™ Releasable RapidSpheres™磁珠50201,1 x 10 mL
    • EasySep™ Dextran RapidSpheres™磁珠50103,1 x 5 mL
    • EasySep™ Release 缓冲液(浓缩),1 x 10 mL
  • EasySep™人CD4+CD127low CD25+调节性T细胞分选试剂盒(产品号 #18063RF)
    • EasySep™人CD25正选抗体混合物,1 mL
    • EasySep™人CD127high去除抗体混合物,1 mL
    • EasySep™人CD4+ T细胞富集抗体混合物,1 mL
    • EasySep™ Releasable RapidSpheres™磁珠,1 mL
    • EasySep™ Dextran RapidSpheres™磁珠,2 x 1 mL
    • EasySep™ Release 缓冲液,2 x 1 mL
    • RoboSep™ 缓冲液(产品号 #20104)
    • RoboSep™过滤吸头(产品号 #20125)x 2
    • EasySep™ EasyTube™-14(产品号 #20128)

总览

使用EasySep™人CD4+CD127lowCD25+调节性T细胞分选试剂盒,可轻松从新鲜或冻存的人外周血单个核细胞(PBMCs)或白细胞单采术样本中通过免疫磁珠正选获得高纯度且不带磁珠的人CD4+CD127lowCD25+调节性T细胞(Tregs)。EasySep™技术结合单克隆抗体的特异性和无柱磁分选系统的简便性,已在发表的研究中广泛应用超过20年。

在该EasySep™正选流程中,目的细胞首先被识别CD25的抗体复合物和EasySep™ Releasable RapidSpheres™可解离磁珠标记。与传统永久结合在目的细胞上的磁珠不同,这些磁珠可以被解离。使用EasySep™磁极分离后,通过解离剂去除EasySep™分选的CD25+细胞上结合的磁珠,同时不需要的非Tregs细胞被识别并去除。最终分选后的细胞中含有高表达FOXP3的高纯度CD4+CD127lowCD25+细胞,可立即用于下游应用。也可同时分离CD4+CD25-应答T细胞以进行功能学研究。使用该EasySep™试剂盒分选之后,细胞表面仍结合有抗体复合物,并可能与Brilliant Violet™偶联的抗体、聚乙二醇修饰的蛋白质或其他化学相关配体相互作用。

如需从白细胞单采术样本中大规模分选CD4+CD127lowCD25+ Tregs,请参见大包装(1x10^10 个细胞)试剂盒(产品号 #100-1136)。

了解更多EasySep™免疫磁珠技术的工作原理,或者如何通过RoboSep™实现全自动化免疫磁珠细胞分选。或者选择用EasySep™人CD4+CD127lowCD25+调节性T细胞分选试剂盒分离的即用型、符合伦理来源的原代人外周血冻存CD4+CD25+CD127lowFOXP3+ T细胞(Tregs)。探索更多为您的实验流程优化的产品,包括培养基、补充剂、抗体等配套试剂。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • Easy 50 EasySep™ Magnet (Catalog #18002) • RoboSep™-S (Catalog #21000) • Easy 250 EasySep™ Magnet (Catalog #100-0821)
 
亚型
细胞分选试剂盒
 
细胞类型
T 细胞,T 细胞,CD4+,T 细胞,调节性细胞
 
种属

 
样本来源
Leukapheresis,PBMC
 
筛选方法
Positive
 
应用
细胞分选
 
品牌
EasySep,RoboSep
 
研究领域
免疫
 

Data Figures

Typical Treg Isolation Using EasySep™ Human CD4+CD127lowCD25+ Regulatory T Cell Isolation Kit
EasySep™ Human CD4+CD127lowCD25+ Regulatory T Cell Isolation Kit Protocol

Figure 1. Typical EasySep™ Human Regulatory T Cell Isolation Profile When Processing Up to 1x 10^9 Cells Per Isolation

Starting with fresh or previously frozen PBMCs, the regulatory T cell content (CD4+CD25+FOXP3+) of the isolated fraction is typically 85.0 ± 4.8% (mean ± SD). In the above example, the purities of the start and final isolated fractions are 1.8% and 88.2%, respectively.

EasySep™ Human CD4+CD127lowCD25+ Regulatory T Cell Isolation Kit Protocol

EasySep™ Human CD4+CD127lowCD25+ Regulatory T Cell Isolation Kit Protocol for the Separation of Tregs

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
100-1136
Lot #
All
Language
English
Catalog #
18063RF
Lot #
All
Language
English
Catalog #
18063
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
18063RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
18063RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
18063RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
18063RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
18063
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
18063
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
18063
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
18063
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Educational Materials (2)

Publications (4)

Fc$\gamma$ receptor-mediated cross-linking codefines the immunostimulatory activity of anti-human CD96 antibodies. A. Rogel et al. JCI insight 2022 oct

Abstract

New strategies that augment T cell responses are required to broaden the therapeutic arsenal against cancer. CD96, TIGIT, and CD226 are receptors that bind to a communal ligand, CD155, and transduce either inhibitory or activating signals. The function of TIGIT and CD226 is established, whereas the role of CD96 remains ambiguous. Using a panel of engineered antibodies, we discovered that the T cell stimulatory activity of anti-CD96 antibodies requires antibody cross-linking and is potentiated by Fc$\gamma$ receptors. Thus, soluble Fc silent" anti-CD96 antibodies failed to stimulate human T cells whereas the same antibodies were stimulatory after coating onto plastic surfaces. Remarkably the activity of soluble anti-CD96 antibodies was reinstated by engineering the Fc domain to a human IgG1 isotype and it was dependent on antibody trans-cross-linking by Fc$\gamma$RI. In contrast neither human IgG2 nor variants with increased Fc$\gamma$ receptor IIB binding possessed stimulatory activity. Anti-CD96 antibodies acted directly on T cells and augmented gene expression networks associated with T cell activation leading to proliferation cytokine secretion and resistance to Treg suppression. Furthermore CD96 expression correlated with survival in HPV+ head and neck squamous cell carcinoma and its cross-linking activated tumor-infiltrating T cells thus highlighting the potential of anti-CD96 antibodies in cancer immunotherapy."
Ethanol Intoxication and Burn Injury Increases Intestinal Regulatory T Cell Population and Regulatory T Cell Suppressive Capability. M. E. Luck et al. Shock (Augusta, Ga.) 2022 feb

Abstract

Traumatic injuries, such as burn, are often complicated by ethanol intoxication at the time of injury. This leads to a myriad of complications and post-burn pathologies exacerbated by aberrant immune responses. Recent findings suggest that immune cell dysfunction in the gastrointestinal system is particularly important in deleterious outcomes associated with burn injuries. In particular, intoxication at the time of burn injury leads to compromised intestinal T cell responses, which can diminish intestinal immunity and promote bacterial translocation, allowing for increased secondary infections in the injured host and associated sequelae, such as multiple organ failure and sepsis. Regulatory T cells (Treg) have been identified as important mediators of suppressing effector T cell function. Therefore, the goal of this study was to assess the effects of ethanol intoxication and burn injury on Treg populations in small intestinal immune organs. We also evaluated the suppressive capability of Tregs isolated from injured animals. Male C57BL/6 mice were gavaged with 2.9?Šg/kg ethanol before receiving a ˆ¼12.5% total body surface area scald burn. One day after injury, we identified a significant increase in Tregs number in small intestine Peyer's patches (ˆ¼?—1.5) and lamina propria (ˆ¼?—2). Tregs-producing cytokine IL-10 were also increased in both tissues. Finally, Tregs isolated from ethanol and burn-injured mice were able to suppress proliferation of effector T cells to a greater degree than sham vehicle Tregs. This was accompanied by increased levels of IL-10 and decreased levels of pro-proliferative cytokine IL-2 in cultures containing ethanol + burn Tregs compared with sham Tregs. These findings suggest that Treg populations are increased in intestinal tissues 1 day following ethanol intoxication and burn injury. Tregs isolated from ethanol and burn-injured animals also exhibit a greater suppression of effector T cell proliferation, which may contribute to altered T cell responses following injury.
Identification of a CD4+ T cell line with Treg-like activity. T. H. Ho et al. Human immunology 2022 apr

Abstract

Regulatory T cells (Tregs) suppress adaptive immunity and inflammation. Although they play a role in suppressing anti-tumor responses, development of therapeutics that target Tregs is limited by their low abundance, heterogeneity, and lack of specific cell surface markers. We isolated human PBMC-derived CD4+ CD25high Foxp3+ Tregs and demonstrate they suppress stimulated CD4+ PBMCs in a cell contact-dependent manner. Because it is not possible to functionally characterize cells after intracellular Foxp3 staining, we identified a human T cell line, MoT, as a model of human Foxp3+ Tregs. Unlike Jurkat T cells, MoT cells share common surface markers consistent with human PBMC-derived Tregs such as: CD4, CD25, GITR, LAG-3, PD-L1, CCR4. PBMC-derived Tregs and MoT cells, but not Jurkat cells, inhibited proliferation of human CD4+PBMCs in a ratio-dependent manner. Transwell membrane separation prevented suppression of stimulated CD4+PBMC proliferation by MoT cells and Tregs, suggesting cell-cell contact is required for suppressive activity. Blocking antibodies against PD-L1, LAG-3, GITR, CCR4, HLA-DR, or CTLA-4 did not reverse the suppressive activity.We show that human PBMC-derived Tregs and MoT cells suppress stimulated CD4+PBMCs in a cell contact-dependent manner, suggesting that a Foxp3+Treg population suppresses immune responses by an uncharacterized cell contact-dependent mechanism.

更多信息

更多信息
Species Human
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • Easy 50 EasySep™ Magnet (Catalog #18002) • RoboSep™-S (Catalog #21000) • Easy 250 EasySep™ Magnet (Catalog #100-0821)
Sample Source Leukapheresis, PBMC
Selection Method Positive
标记抗体
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。